Bicara Therapeutics Q3 net loss widens on higher R&D costs
BCAX•Bicara Therapeutics reported a Q3 net loss of $71.25 million as research and development and administrative costs increased. It ended the quarter with $442.3 million in cash and expects existing funds to support operations into the first half of 2029.
1. Quarterly results
Bicara Therapeutics’ Q3 net loss widened as research and development and administrative costs increased. The company reported a $71.25 million net loss and a $75.71 million loss from operations.
2. Cash and trial outlook
The company ended Q3 with $442.3 million in cash and expects it to fund operations into the first half of 2029. It expects topline results from the FORTIFI-HN01 interim analysis in mid-2027; enrollment in the pivotal trial for HPV-negative head and neck cancer is substantial.
